Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Eneboparatide by Amolyt Pharma for Hypoparathyroidism: Likelihood of Approval
Eneboparatide is under clinical development by Amolyt Pharma and currently in Phase III for Hypoparathyroidism. According to GlobalData, Phase III...